Research ExplorerPublicationsNeue Aspekte in der Therapie von Schilddrüsenkarzinomen

Neue Aspekte in der Therapie von Schilddrüsenkarzinomen

Standard

Neue Aspekte in der Therapie von Schilddrüsenkarzinomen : Highlights des ASCO-Kongresses 2015. / Lörincz, B B; Topp, S; Knecht, R.

In: HNO, Vol. 63, No. 9, 09.2015, p. 625-8.

Research output: SCORING: Contribution to journal › Conference article in journal › Research › peer-review

Harvard

Lörincz, BB, Topp, S & Knecht, R 2015, 'Neue Aspekte in der Therapie von Schilddrüsenkarzinomen: Highlights des ASCO-Kongresses 2015', HNO, vol. 63, no. 9, pp. 625-8. https://doi.org/10.1007/s00106-015-0052-3

APA

Lörincz, B. B., Topp, S., & Knecht, R. (2015). Neue Aspekte in der Therapie von Schilddrüsenkarzinomen: Highlights des ASCO-Kongresses 2015. HNO, 63(9), 625-8. https://doi.org/10.1007/s00106-015-0052-3

Vancouver

Lörincz BB, Topp S, Knecht R. Neue Aspekte in der Therapie von Schilddrüsenkarzinomen: Highlights des ASCO-Kongresses 2015. HNO. 2015 Sep;63(9):625-8. https://doi.org/10.1007/s00106-015-0052-3

Bibtex

@article{a16bc02eabfd4606919a35dc0ec3743e,
title = "Neue Aspekte in der Therapie von Schilddr{\"u}senkarzinomen: Highlights des ASCO-Kongresses 2015",
abstract = "At the beginning of June 2015, the Annual Meeting of the American Society of Clinical Oncology (ASCO) took place in Chicago. A total of 24 studies in the field of thyroid oncology were presented, being discussed in the present review article according to the degree of cancer cell differentiation. The leading curative treatment modality is still surgery. Kinase inhibitors are used primarily in the context of palliative treatment concepts. The most recent treatment options in thyroid oncology, both surgical and medical, are summarized in the following article.",
author = "L{\"o}rincz, {B B} and S Topp and R Knecht",
year = "2015",
month = sep,
doi = "10.1007/s00106-015-0052-3",
language = "Deutsch",
volume = "63",
pages = "625--8",
journal = "HNO",
issn = "0017-6192",
publisher = "Springer",
number = "9",

}

RIS

TY - JOUR

T1 - Neue Aspekte in der Therapie von Schilddrüsenkarzinomen

T2 - Highlights des ASCO-Kongresses 2015

AU - Lörincz, B B

AU - Topp, S

AU - Knecht, R

PY - 2015/9

Y1 - 2015/9

N2 - At the beginning of June 2015, the Annual Meeting of the American Society of Clinical Oncology (ASCO) took place in Chicago. A total of 24 studies in the field of thyroid oncology were presented, being discussed in the present review article according to the degree of cancer cell differentiation. The leading curative treatment modality is still surgery. Kinase inhibitors are used primarily in the context of palliative treatment concepts. The most recent treatment options in thyroid oncology, both surgical and medical, are summarized in the following article.

AB - At the beginning of June 2015, the Annual Meeting of the American Society of Clinical Oncology (ASCO) took place in Chicago. A total of 24 studies in the field of thyroid oncology were presented, being discussed in the present review article according to the degree of cancer cell differentiation. The leading curative treatment modality is still surgery. Kinase inhibitors are used primarily in the context of palliative treatment concepts. The most recent treatment options in thyroid oncology, both surgical and medical, are summarized in the following article.

U2 - 10.1007/s00106-015-0052-3

DO - 10.1007/s00106-015-0052-3

M3 - Konferenzaufsatz in Fachzeitschrift

C2 - 26319428

VL - 63

SP - 625

EP - 628

JO - HNO

JF - HNO

SN - 0017-6192

IS - 9

ER -